Develops, manufactures and commercializes genetically engineered therapeutic fibroblast growth factors (FGFs) for ophthalmology, dermatology and wound-healing indications. Markets six approved biologic therapies and maintains an R&D pipeline of growth-factor and antibody programs across multiple clinical stages.